eFlow® rapid
Clinical Data

Pharmacokinetics
Compliance
Tolerability
Inhalation of Tobramycin (TOBI*) via eFlow® rapid versus PARI LC PLUS®

Clinical data confirms: 1)

- Reduced inhalation time by more than half

- Reduced systemic serum levels

- Higher mean tobramycin sputum levels
  Mean tobramycin sputum levels were 1.8 fold higher for TOBI* administered via the eFlow® rapid than the PARI LC PLUS®.

- Maintained a similar safety profile
  Adverse events all mild-moderate. No clinically significant bronchospasm occurred.


Actual surveys about patient compliance:

eFlow® rapid had a positive influence on adherence 2)

Inhalation time (Min)

Tobramycin serum concentration profiles: Day 15

Mean tobramycin serum concentration profiles after the last dose from each nebulizer. Bars represent 95% confidence intervals.

Adherence (Visual analog scale)

The reduction in inhalation time of about two thirds with the eFlow® rapid was the most important advantage over conventional jet nebulizers.
Tolerability

Hypertonic Saline 6% via eFlow® rapid

Clinical data confirms: 4)

- Good tolerability
- Improved Compliance

40 adult CF patients inhaled two or four times daily 4ml of 6% hypertonic saline with the eFlow® rapid. Time for delivery was 3.9 ± 0.9 minutes, FEV1 improved by 5% after two weeks with twice daily HS.

Outcomes of the bid treatment were comparable to those with the qid regimen, but tolerability was a lot better with HS administered only twice daily (refer to table). 90% of the subjects said that they would use this therapy on a long term basis.


Therapy recommendation:

- Inhalation of 4 ml of 6% hypertonic saline twice daily
- Inhalation time for 4 ml: approx 4 min

NEW!

MucoClear® 6%

Inhalationslösung zur Sekretmobilisation in den unteren Atemwegen

20 x 4 ml NaCl (6%) – steril
Ohne Konservierungsmittel
Für Kinder unter 4 Jahren hamodynamisch

Medical Device Class I, sterile
More information: www.mucoclear.info

More Information

PARI Pharma GmbH
Moosstraße 3 • D- 82319 Starnberg
PARI Service Center: 08151/279-279
E-mail: info@pari.de
www.pari.de
www.eFlowrapid.info

© 2008 PARI Pharma GmbH · 17800048 · Q08